<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03878719</url>
  </required_header>
  <id_info>
    <org_study_id>ARRAY-162-115</org_study_id>
    <secondary_id>C4221011</secondary_id>
    <nct_id>NCT03878719</nct_id>
  </id_info>
  <brief_title>Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma</brief_title>
  <official_title>A Multicenter, Open-label Phase 1b Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pierre Fabre Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter Phase 1b, open-label study to evaluate the pharmacokinetic, safety and
      efficacy of binimetinib and encorafenib co-administered to adolescent patients with BRAF
      V600-mutant advanced/metastatic melanoma. The study consists of a Safety Run-in Phase to
      determine the RDE (recommended dose in expansion), followed by an Expansion Phase.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 12, 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameter (time to reach the maximum observed plasma concentration Cmax [Tmax]) for binimetinib</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Cmax) for binimetinib</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (time of last PK sample [Tlast]) for binimetinib</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (area under the plasma concentration-time curve from time zero to Tlast [AUClast]) for binimetinib</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Tmax) for binimetinib's active metabolite (AR00426032)</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Cmax) for AR00426032</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Tlast) for AR00426032</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (AUClast) for AR00426032</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Tmax) for encorafenib</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Cmax) for encorafenib</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Tlast) for encorafenib</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (AUClast) for encorafenib</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Tmax) for encorafenib's metabolite (LHY746)</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Cmax) for LHY746</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Tlast) for LHY746</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (AUClast) for LHY746</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (trough concentration [Ctrough]) for binimetinib</measure>
    <time_frame>at time zero Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (trough concentration [Ctrough]) for binimetinib</measure>
    <time_frame>at time zero Day 1 of Cycle 2, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (trough concentration [Ctrough]) for binimetinib</measure>
    <time_frame>at time zero Day 1 of Cycle 3, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Ctrough) for AR00426032</measure>
    <time_frame>at time zero Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Ctrough) for AR00426032</measure>
    <time_frame>at time zero Day 1 of Cycle 2, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Ctrough) for AR00426032</measure>
    <time_frame>at time zero Day 1 of Cycle 3, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Ctrough) for encorafenib</measure>
    <time_frame>at time zero Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Ctrough) for encorafenib</measure>
    <time_frame>at time zero Day 1 of Cycle 2, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Ctrough) for encorafenib</measure>
    <time_frame>at time zero Day 1 of Cycle 3, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Ctrough) for LHY746</measure>
    <time_frame>at time zero Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Ctrough) for LHY746</measure>
    <time_frame>at time zero Day 1 of Cycle 2, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Ctrough) for LHY746</measure>
    <time_frame>at time zero Day 1 of Cycle 3, 28 day cycles</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events (AEs)</measure>
    <time_frame>From informed consent up to 30 days following last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of dose-limiting toxicities (DLTs)</measure>
    <time_frame>Duration of treatment for safety run-in phase, approximately 6 months, 28 day cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Palatability score for the pediatric formulations as assessed by an age-appropriate questionnaire for binimetinib</measure>
    <time_frame>Through Cycle 3 Day 1 in patients receiving the pediatric formulations in the Expansion Phase, 28 day cycles</time_frame>
    <description>Five-point Hedonic scale from 1 to 5, 5=really good</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Palatability score for the pediatric formulations as assessed by an age-appropriate questionnaire for encorafenib</measure>
    <time_frame>Through Cycle 3 Day 1 in patients receiving the pediatric formulations in the Expansion Phase, 28 day cycles</time_frame>
    <description>Five-point Hedonic scale from 1 to 5, 5=really good</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) assessed by the investigator, based on Response Criteria Evaluation in Solid Tumors (RECIST) v1.1</measure>
    <time_frame>Duration of treatment, approximately 6 months, 28 day cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Duration of treatment, approximately 6 months, 28 day cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>Duration of treatment, approximately 6 months, 28 day cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Duration of treatment, approximately 6 months, 28 day cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One-year survival rate</measure>
    <time_frame>From first dose up to 1 year after treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in bone densitometry based on dual energy X-ray absorptiometry (DEXA) scan.</measure>
    <time_frame>Duration of treatment, approximately 6 months, 28 day cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in calcium-phosphorus product (Ca × P)</measure>
    <time_frame>Duration of treatment, approximately 6 months, 28 day cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Safety Run-in Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>binimetinib taken twice daily (BID) and
encorafenib taken once daily (QD)
Dose levels by patient body surface area (BSA) for binimetinib and encorafenib tablets/capsules are specified in the protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>binimetinib taken twice daily (BID) and
encorafenib taken once daily (QD)
Dose levels by patient body surface area (BSA) for binimetinib and encorafenib tablets/capsules and pediatric formulations are specified in the protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>binimetinib</intervention_name>
    <description>taken orally</description>
    <arm_group_label>Expansion Phase</arm_group_label>
    <arm_group_label>Safety Run-in Phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>encorafenib</intervention_name>
    <description>taken orally</description>
    <arm_group_label>Expansion Phase</arm_group_label>
    <arm_group_label>Safety Run-in Phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

        Patients must meet all of the following criteria to be eligible for enrollment in the
        study.

          -  Histologically confirmed diagnosis of locally advanced, unresectable or metastatic
             cutaneous melanoma or unknown primary melanoma American Joint Committee on Cancer
             Stage IIIB, IIIC, or IV.

          -  Presence of BRAF V600E or V600K mutation in tumor tissue as determined by a local or
             central laboratory

          -  Adequate cardiac function:

               -  Left ventricular ejection fraction (LVEF) ≥ 50% as determined by ECHO or
                  multi-gated acquisition (MUGA) scan and above the institutional lower limit of
                  normal (LLN);

               -  Triplicate average baseline QTcF value ≤ 450 ms.

          -  Adequate bone marrow, organ function, and laboratory parameters:

               -  Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L;

               -  Hemoglobin ≥ 9 g/dL with or without transfusions;

               -  Platelets ≥ 75 × 10⁹/L without transfusions;

               -  Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ≤ 2.5 ×
                  upper limit of normal (ULN); in patients with liver metastases ≤ 5 × ULN;

               -  Total bilirubin ≤ 1.5 × ULN;

               -  Creatinine ≤ 1.5 × institutional ULN for age, or calculated creatinine clearance
                  ≥ 70 mL/min/1.73 m² (following Schwartz formula).

          -  Adequate performance status at Screening:

               -  Patients &lt; 16 years old: Lansky Performance Scale score ≥ 80

               -  Patients 16 to 17 years old: Karnofsky Performance Scale score ≥ 80

        Key Exclusion Criteria:

        Patients meeting any of the following criteria are not eligible for enrollment in the
        study.

          -  Uveal or mucosal melanoma.

          -  Brain metastases that are uncontrolled or symptomatic, require steroids, are
             potentially life-threatening or have required radiation within 28 days prior to
             starting study drug.

          -  History or current evidence of retinal vein occlusion (RVO) or current risk factors
             for RVO

          -  Prior therapy with a BRAF inhibitor (e.g., dabrafenib, vemurafenib) and/or a MEK
             inhibitor (e.g., trametinib, cobimetinib).

          -  Impaired cardiovascular function or clinically significant cardiovascular disease,
             including any of the following:

               -  History of acute coronary syndromes (including myocardial infarction, unstable
                  angina, coronary artery bypass grafting, coronary angioplasty or stenting) &lt; 6
                  months prior to screening,

               -  Symptomatic chronic heart failure, history or current evidence of clinically
                  significant cardiac arrhythmia and/or conduction abnormality &lt; 6 months prior to
                  screening except atrial fibrillation and paroxysmal supraventricular tachycardia.

          -  Concurrent neuromuscular disorder associated with elevated creatine kinase (CK)

          -  Uncontrolled arterial hypertension despite medical treatment

          -  Presence of BRAFʷͭ or indeterminate melanoma in tumor tissue.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Praha</city>
        <zip>11000</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardy</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Siena</city>
        <state>Tuscany</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Newtown</city>
        <state>Wellington</state>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=ARRAY-162-115</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 20, 2019</study_first_submitted>
  <study_first_submitted_qc>March 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adolescent</keyword>
  <keyword>BRAF V600K</keyword>
  <keyword>BRAF V600E</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

